A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Confirmation of onychomycosis by positive mycological (KOH) staining and positive culture from affected great toenail(s).

• Appearance of onychomycosis involving 20% to 60% of 1 (or both) affected great toenail(s), as determined by visual inspection after the nail has been trimmed. If the percentage of infection is outside this range but is still considered appropriate for this study, based on the overall impression of the Principal Investigator (PI), participation can be considered in consultation with the Medical Monitor (MM). The visual inspection results of the appearance of onychomycosis involving 20% to 60% of 1 (or both) affected great toenail(s) will be reviewed by the Sponsor before enrollment.

• The combined thickness of the distal nail plate at the associated hyperkeratotic nail bed is \< 2 mm.

• Adult males and females, 18 to 70 years of age (inclusive) at the time of Screening.

• In good general health, with no significant medical history, and no clinically significant abnormalities on physical examination or ECG at Screening and/or before the first administration of IP at the discretion of the PI or designee. Participants with mild stable disease may be considered eligible at the discretion of the PI or designee.

• Body mass index (BMI) between 17.5 and 35.0 kg/m2, inclusive, at Screening.

Locations
Other Locations
New Zealand
New Zealand Clinical Research Christchurch
RECRUITING
Christchurch
Contact Information
Primary
Jason (Jong-Seung) Lee
jason_lee@amtixbio.com
31 5175 8215
Time Frame
Start Date: 2024-07-01
Estimated Completion Date: 2026-01-30
Participants
Target number of participants: 120
Treatments
Experimental: ATB1651-102 Cohort 1
The planned ATB1651 dose of 3% solution to each infected toenail once daily for 12 weeks (follow up for 24 weeks) Twenty-five participants are expected to enroll per cohort.
Experimental: ATB1651-102 Cohort 2
The planned ATB1651 dose of 3% solution to each infected toenail once daily for 20 weeks follow up for 16 weeks) Twenty-five participants are expected to enroll per cohort.
Experimental: ATB1651-102 Cohort 3
The planned ATB1651 dose of 3% solution to each infected toenail twice daily for 12weeks follow up for 24 weeks).~Twenty-five participants are expected to enroll per cohort.
Experimental: ATB1651-102 Cohort 4
The planned ATB1651 dose of 5% solution to each infected toenail once daily for 12weeks follow up for 24 weeks).~Twenty-five participants are expected to enroll per cohort.
Placebo_comparator: Placebo
Matching placebo to the IP per cohort.~Five participants are expected to be enrolled per cohort.
Related Therapeutic Areas
Sponsors
Leads: AmtixBio Co., Ltd.

This content was sourced from clinicaltrials.gov